Effectiveness of personalized antiplatelet therapy in patients undergoing coronary stenting: meta-analysis

Abstract

Listen

Translate article

Background . Prevention of complications in patients after coronary stenting by selection of personalized antiplatelet therapy (PAPT) based on platelet function test and genetic analysis have been actively studied. However, it is still an issue of concern. The article presents a meta-analysis of the recent PAPT studies. Aim . To evaluate the effectiveness of personalized antiplatelet therapy in patients undergoing coronary stenting. Methods Fifteen studies with the total of 9,497 patients were included in the meta-analysis. The PAPT studies were searched using the PubMed, Embase and Cochrane Library. Results . PAPT reduces the risk of major adverse cardiovascular events (RR 0.58, 95% CI 0.42-0.80, p = 0.001), stent thrombosis (RR 0.60, 95% CI 0.41-0.87, p = 0.008) and myocardial infarction (RR 0.43, 95% CI 0.21-0.88, p = 0.02) compared with patients without PAPT. However, no significant differences were found in cardiovascular mortality (RR 0.77, 95% CI 0.51-1.16, p = 0.21), bleeding (RR 0.96, 95% CI 0.81-1.13, p = 0.59) and ischemic stroke (RR 0.81, 95% CI 0.39-1.66, p = 0.57). The effectiveness of PAPT in reducing major adverse cardiovascular events was mainly in patients with high platelet reactivity during dual antiplatelet therapy (RR 0.46, 95% CI 0.27-0.80, p = 0.006). Conclusion . Personalized antiplatelet therapy significantly reduces the risk of stent thrombosis, myocardial infarction and other major adverse cardiovascular events in patients with coronary artery stenting.